MTA3: Metastasis Associated 1 Family Member 3
A core component of the NuRD chromatin remodeling complex involved in transcriptional repression and cancer progression.
Gene Information Card
| Symbol | MTA3 |
|---|---|
| Full Name | Metastasis Associated 1 Family Member 3 |
| Gene Type | Protein coding |
| Chromosomal Location | 2p21 |
| NCBI Gene ID | 57504 ncbi.nlm.nih.gov/gene/57504 |
| Ensembl ID | ENSG00000115970 |
| UniProt ID | Q9BTC8 |
| OMIM ID | 609050 |
| HGNC ID | 7411 |
| Aliases | KIAA1266, MTA1L1 |
Description
MTA3 (Metastasis Associated 1 Family Member 3) encodes a protein that is a core component of the nucleosome remodeling and deacetylase (NuRD) complex. This complex mediates ATP-dependent chromatin remodeling and histone deacetylase activity, playing a key role in transcriptional repression. MTA3 is involved in cell differentiation, proliferation, and migration, and its dysregulation is associated with various cancers, particularly breast cancer.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast Cancer | MTA3 represses Snail transcription, maintaining epithelial phenotype; loss promotes EMT and metastasis. | PMID: 16642020 |
| Endometrial Cancer | MTA3 overexpression correlates with tumor grade and invasion. | PMID: 23429704 |
| Gastric Cancer | MTA3 downregulation associated with poor prognosis and increased metastasis. | PMID: 25944712 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Breast | 12.5 | Medium |
| Endometrium | 15.3 | Medium |
| Lung | 8.7 | Low |
| Liver | 6.2 | Low |
| Brain | 4.1 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| MCF7 | 18.2 | Breast cancer cell line |
| HeLa | 22.5 | Cervical cancer cell line |
| A549 | 9.8 | Lung cancer cell line |
| HepG2 | 7.3 | Liver cancer cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1012C>T | Missense | 0.02% | p.Arg338Trp; potential loss of function |
| c.1456_1457del | Frameshift | 0.01% | p.Glu486fs; truncation, likely loss of function |
| c.789G>A | Synonymous | 0.05% | p.Pro263Pro; no amino acid change |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense mutations that truncate the protein or disrupt the SANT domain are predicted to impair NuRD complex assembly and transcriptional repression.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported in MTA3.
Dominant Negative (DN)
Missense mutations in the ELM2 domain may interfere with NuRD complex function in a dominant-negative manner, though evidence is limited.
View complete mutation data：
Gene Ontology (GO)
| • protein binding (GO:0005515) | • histone deacetylase activity (GO:0004407) |
| • regulation of transcription by RNA polymerase II (GO:0006357) | • chromatin remodeling (GO:0006338) |
| • nucleus (GO:0005634) |
Pathways
• NuRD complex pathway (Reactome: R-HSA-3214847)
• Chromatin modifying enzymes (KEGG: hsa05200)
Protein Summary
MTA3 is a 594-amino acid protein containing a BAH domain, an ELM2 domain, and a SANT domain. It functions as a scaffold within the NuRD complex, linking histone deacetylase and chromatin remodeling activities. MTA3 is highly expressed in hormone-responsive tissues and plays a critical role in maintaining epithelial differentiation by repressing Snail transcription. Its loss is associated with epithelial-mesenchymal transition and cancer metastasis.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| MTA3 Knockout HEK293 Cell Line | EDJ-KQ14326 | Human | 57504 | Details Get a Quote |
| MTA3 Knockout A-549 Cell Line | EDJ-KQ44421 | Human | 57504 | Details Get a Quote |
| MTA3 Knockout HCT 116 Cell Line | EDJ-KQ44422 | Human | 57504 | Details Get a Quote |
| MTA3 Knockout HeLa Cell Line | EDJ-KQ44423 | Human | 57504 | Details Get a Quote |
